By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Momenta Pharmaceuticals, Inc. 

675 West Kendall Street

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-491-9700 Fax: 617-621-0431


Momenta is a leader in the analysis, characterization, and design of complex pharmaceutical products. Our scientific foundation is a set of tools and methods that enable one to develop a deep understanding of the links between a compound’s chemical structure, its manufacturing process and its biological function. These innovative tools enable us to develop complex generics and biosimilars as well as facilitate the discovery of novel medicines. We believe that by applying our innovative technology to our discovery and development programs, we have the potential to create a robust pipeline of innovative generic and novel medicines.

Our success is a result of our committed and talented people. We attract scientists exceptionally skilled in integrating information from diverse technical disciplines and task them with challenging characterization, process, and biology problems. Using this approach, we have designed tools and methods to understand the structure (characterization of chemical components), structure-process (design and control of manufacturing process) and structure-activity (relationships between structure and biological and clinical activity) of complex mixture drugs. From this knowledge comes a diversified product development pipeline consisting of both generic and novel complex mixture drugs designed to address a variety of medical needs.

In July 2010, Momenta announced the FDA approval of our first drug, Enoxaparin Sodium Injection developed in collaboration with Sandoz . Enoxaparin is a more affordable, generic version of Lovenox® (enoxaparin sodium injection), which is indicated for the prophylaxis of deep vein thrombosis (DVT). Enoxaparin Sodium Injection is a heparin-based complex mixture drug that was developed using our innovative scientific approach. Following this initial success, we are applying a similar approach to developing a generic version of Copaxone® (glatiramer acetate), a complex mixture of polypeptides indicated for the treatment of relapsing-remitting multiple sclerosis. We have also added biosimilars, which are highly similar and potentially interchangeable biologics to our development pipeline. And finally, with the knowledge acquired from our complex generic and biosimilars business, we are our using our tools and technology to design and improve the structures of proteins and heparin-derived products to create novel medicines . Our goal is to leverage the multi-targeting nature of complex mixture molecules to develop novel products which could positively modulate multiple pathways in a disease. Additionally, in December 2011 we acquired selected assets relating to sialylation technology. Sialic acid is a type of sugar modification on selected proteins that is understood to regulate anti-inflammatory and immunomodulatory function. These assets add to our core ability to modify and engineer protein backbones to precisely regulate biological networks and develop novel biologic product candidates.

Lovenox® is a registered trademark of Sanofi-Aventis. Copaxone® is a registered trademark of Teva Pharmaceutical Industries Ltd.

Key Statistics

Ownership: Public

Web Site: Momenta Pharmaceuticals, Inc.
Employees: 270
Symbol: MNTA


Company News
Momenta Pharmaceuticals, Inc. (MNTA) Announces Publication Revealing Development Of A Novel Process To Generate High-Quality Hyper-Sialylated IVIg Drug Candidate In PNAS 3/3/2015 7:15:19 AM
Momenta Pharmaceuticals, Inc. (MNTA) To Webcast Presentation At Cowen and Company's 35th Annual Health Care Conference 2/18/2015 8:13:55 AM
Momenta Pharmaceuticals, Inc. (MNTA) Reports Fourth Quarter and Year End 2014 Financial Results 2/17/2015 7:39:18 AM
Momenta Pharmaceuticals, Inc. (MNTA) Announces Date Of Fourth Quarter And Year End 2014 Financial Results Conference Call And Webcast 2/3/2015 9:11:09 AM
Momenta Pharmaceuticals, Inc. (MNTA) To Webcast Presentation At Two Upcoming Investor Conferences 1/29/2015 7:53:49 AM
Momenta Pharmaceuticals, Inc. (MNTA) Announces Supreme Court Decision To Remand Generic Copaxone® Case Back To CAFC 1/21/2015 7:42:05 AM
Momenta Pharmaceuticals, Inc. (MNTA) Announces Acceptance Of A Clinical Trial Application In Europe For M923, A Biosimilar Version Of Humira 12/1/2014 9:56:16 AM
Momenta Pharmaceuticals, Inc. (MNTA)' Necuparanib Receives Fast Track Designation From The FDA For The Treatment Of Patients With Metastatic Pancreatic Cancer 12/1/2014 7:32:08 AM
Momenta Pharmaceuticals, Inc. (MNTA) To Webcast Presentation At 2014 Deutsche Bank (DB) BioFEST 11/25/2014 11:41:23 AM
Momenta Pharmaceuticals, Inc. (MNTA) To Webcast Presentation At Three Upcoming Investor Conferences 11/6/2014 1:08:49 PM